Advanced Search

Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 August;60(4) > Minerva Cardioangiologica 2012 August;60(4):405-13



A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

Frequency: Bi-Monthly

ISSN 0026-4725

Online ISSN 1827-1618


Minerva Cardioangiologica 2012 August;60(4):405-13


Severe intermittent claudication: pge1 treatment. A 40-week registry, efficacy and costs

Luzzi R. 1, Belcaro G. 1, Ippolito E. 1, Dugall M. 1, Cesarone M. R. 1, Scoccianti M. 1, Errichi B. M. 1, Pellegrini L. 1, Ciammaichella G. 1, Ledda A. 1, Ricci A. 1, Cornelli U. 1, Feragalli B. 1, Hosoi M. 1, Corsi M. 1, Simeone E. 1, Agus G. B. 2

1 Department of Biomedical Sciences, Irvine3 Circulation/Vascular Labs , Chieti-Pescara University, Italy, San Valentino Vascular Screening Project, Pescara, Italy;
2 Department of Clinical and Community Sciences, University of Milan, Milan, Italy

AIM: Intermittent claudication (IC) in peripheral vascular disease is characterized by lower limb pain appearing on effort. Treatment with PGE1 has been successfully used to manage IC patients. This registry has evaluated safety and costs of PGE1 in the management of IC.
METHODS: In this study a long-term treatment protocol (LTP), a short-term protocol (STP) and an outpatient (OP), “on-demand” treatment have been compared. A treadmill effort test has been used to evaluate walking distance. The follow up for these three protocols was 40 weeks. PGE1 treatment was associated to a risk reduction plan and to an exercise program.
RESULTS:The final analysis has included 252 LTP patients, 223 STP patients and 284 OP patients (total 659 valid cases). A group of 171 comparable patients not treated with PGE1 was used for a parallel comparison. Cardiovascular mortality and morbidity has been evaluated in 731 PGE1 patients completing 24 months of follow up. All protocols have been well tolerated. No side effects were observed. The lower cost has been observed for OP patients. In the long term, mortality and morbidity were lower in patients treated with PGE1 in comparison with patients not treated with PGE1.
CONCLUSION: Considering costs and results (increase in walking distance) and improvement in Karnofsky scale the STP plan appears to be better than LTP for IC patients. The OP, “on-demand” treatment offers further improvements. This last treatment plan is simpler; the plan allows better timing for exercise. The treatment can be used even in non-specialized centers.

language: Italian


top of page